🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
27.40
-0.14 (-0.51%)
At close: Nov 20, 2026, 4:00 PM EST
27.43
+0.03 (0.11%)
After-hours: Nov 20, 2026, 7:59 PM EST
← View all transcripts

Investor update

Nov 12, 2026

Summary

Phase II monotherapy showed EASI-75 rates of 59% and 61% at the two highest monthly doses, with favorable tolerability. Phase III trials are underway in atopic dermatitis, asthma and COPD; the AD program includes a dupilumab comparison.

Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the trispecific antibody, tilrekimig. Today's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino, Chief Investor Relations Officer and Senior Vice President. Please go ahead, ma'am. Thank you, and good morning, everyone. I'm Francesca DeMartino, Senior Vice President and Chief Investor Relations Officer. On behalf of the Pfizer team, thank you so much for joining us. Today's event will be recorded and available for replay on our IR website at pfizer.com. As a reminder, our Pfizer Pflash series is intended to serve as an educational deep dive into our pipeline, products, and people. Each event spotlights a specific product, therapeutic, or growth initiative and gives you an opportunity to hear directly from our business leaders. Today's session will begin with a presentation followed by live Q&A. As a reminder, this call is intended only for the investment community, including our sell-side analysts and institutional investors. I want to note that on today's call, we will be making forward-looking statements. I encourage you to view slide two in our presentation and the disclosures in our SEC filings, all of which are available on our IR website at pfizer.com. Forward-looking statements on the call are subject to substantial risks and uncertainties, speak only as of the call's original date, and we undertake no obligation to update or revise any of the statements. I'm joined today by Mike Vincent, Pfizer's Chief Inflammation and Immunology Officer. Following my intro, Mike will speak about our potential first-in-class trispecific antibody, tilrekimig, review recent phase II data in atopic dermatitis, and discuss the broader development plan for this molecule. Christian Antoni, our Chief Development Officer for I&I, will join us for Q&A. Inflammation and immunology, or I&I, is one of Pfizer's R&D's four therapeutic areas of focus and a key part of our targeted strategy to address conditions with high unmet need and large patient populations where our science can deliver the greatest impact. Pfizer's in-house discovery teams have extensive expertise across a broad range of core modalities, including small molecules, vaccines, and especially relevant for today's discussion, biologics such as multispecific antibodies. Here's a select snapshot of our I&I portfolio, which includes small molecules and biologics at multiple stages of development across both new molecular entities and lifecycle management opportunities. This portfolio reflects Pfizer's established capabilities in I&I across both R&D and commercial functions. While we recognize there is significant interest in several of these programs, the remainder of today's presentation will center on tilrekimig, and we ask that you focus your Q&A questions there as well. With that, I will hand it over to Mike. Thank you, Francesca. It's a pleasure to be here. As you mentioned, we've leveraged our expertise across small molecules and biologics to build a robust I&I pipeline and are eager to highlight tilrekimig today. Tilrekimig is an investigational trispecific antibody that targets IL-4, IL-13, and TSLP, three established and complementary drivers of type 2 inflammation. Type 2 inflammation is a misdirected allergy-type immune response that causes the itching, swelling, and airway narrowing seen in the diseases I'll be discussing today. Last month, phase II results for tilrekimig in moderate-severe atopic dermatitis were featured in an oral presentation at the European Academy of Dermatology and Venereology Congress, or EADV. We believe these data provide proof of concept for tilrekimig and support the three pillars of its value proposition. First, robust efficacy. At the top monthly doses studied at week 16, tilrekimig achieved placebo-adjusted response rates of about 50% for EASI-75, defined as a 75% or greater improvement on the Eczema Area and Severity Index. Though cross-trial comparisons have inherent limitations, these results suggest the potential for superior efficacy versus dupilumab, today's standard of care biologic. Key secondary endpoints in an ongoing phase III trial are testing this hypothesis directly in a head-to-head setting. Second, favorable safety. At subcutaneous doses up to 400 milligrams every four weeks, conjunctivitis and injection site reactions in stage 2 of our trial were less frequent than the historical rates reported with dupilumab and comparable to placebo. Third, a pipeline and a product opportunity. Atopic dermatitis is our potential anchor indication, but common biological pathways targeted by tilrekimig drive a host of other type 2 inflammatory diseases. Building on our strong phase II data, we've already started phase III studies in both atopic dermatitis and asthma, with an ongoing phase II/III study in chronic obstructive pulmonary disease, or COPD. I'll walk through each of these pillars before we open it up for Q&A. First, let's review tilrekimig's design, mechanism of action, and the opportunity in atopic dermatitis. Tilrekimig was discovered internally at Pfizer and demonstrates potent binding to IL-4, IL-13, and TSLP. Importantly, it's able to bind each of these targets simultaneously without interference, meaning affinity for one target is not impacted by the presence of the others. IL-4 and IL-13 are the central downstream effectors of type 2 inflammation. Unlike approaches that block their shared receptor, IL-4 receptor alpha, tilrekimig binds the cytokines directly, minimizing clearance. TSLP is an upstream alarmin that initiates and amplifies type 2 inflammation, while also contributing to non-type two inflammation. An engineered Fc extends tilrekimig's half-life to approximately 37 days, supporting once-monthly subcutaneous dosing. Targeting the ligands directly, combined with the extended half-life, may help maintain suppression of free cytokines throughout the dosing interval better than receptor-targeting approaches, such as dupilumab. Importantly, the biological pathways targeted by tilrekimig are clinically validated. As shown in green, each one is the target of an approved therapy. Dupilumab targets the IL-4 receptor alpha, which mediates IL-4 and IL-13 signaling. Tralokinumab and lebrikizumab target the IL-13 cytokine, and tezepelumab targets TSLP. Tilrekimig is designed to target complementary drivers of type 2 inflammation with a single molecule. We believe this combination gives us a strong foundation and a clear basis for differentiation across indications such as atopic dermatitis, asthma, and COPD, subject to clinical trial and regulatory success. Starting with atopic dermatitis, the leading contributor to skin disease burden globally, it's a chronic, relapsing inflammatory condition that carries substantial symptomatic, psychosocial, and economic burden, from persistent itch to disrupted sleep. Approximately 9.8 million people in the U.S. live with a moderate to severe form of the disease. Despite meaningful advances across the current landscape, many patients on advanced systemic therapies still do not achieve treatment targets. Real-world data at six months show that roughly 80% of patients missed optimal targets for skin clearance and itch. Even against more moderate targets, more than a third missed skin clearance goals, and two-thirds missed itch goals. Importantly, no biologic has demonstrated superiority to dupilumab, the current standard of care. Next, I'll walk you through why we believe tilrekimig could potentially demonstrate improved efficacy versus dupilumab in our ongoing phase III study. It starts with potency. In preclinical in vitro studies, we compared tilrekimig with dupilumab and tezepelumab in a white blood cell expression assay. This assay is a functional measure of IL-4, IL-13, and TSLP signaling. The y-axis shows the level of inhibition achieved with a given concentration of antibody, with the measure of the concentration shown on the x-axis. Curves shifted to the left are therefore indicative of more potent antibody. As you can see, tilrekimig showed approximately 13-fold higher functional potency than dupilumab against IL-4-stimulated signaling. In the middle, its potency against IL-13 signaling was approximately seven-fold higher than dupilumab. On the right, tilrekimig inhibited TSLP signaling at levels comparable to tezepelumab, an anti-TSLP antibody approved for severe asthma. We believe greater functional potency against IL-4 and IL-13, together with the additional mechanism of action targeting TSLP, may drive enhanced efficacy versus dupilumab. Beyond potency, our hypothesis also rests on inhibition of multiple complementary pathways. To further explore the potential for additive effects of TSLP blockade, investigators stimulated human skin explants with IL-4, IL-13, or with TSLP, and then profiled the resulting gene expression. These data were presented at a poster in EADV. As the heat map shows, IL-4 and IL-13 and TSLP signaling drive both shared and distinct inflammatory pathways. IL-4 and IL-13 changed the expression of 910 genes by more than twofold. TSLP changed 179 genes. Only 44 responded to both, suggesting that the overlap is limited, and blocking one pathway leaves much of the other active. This highlights an opportunity to achieve potentially additive efficacy by blocking IL-4 and IL-13 and TSLP signaling together with tilrekimig in atopic dermatitis versus blockade of either alone. With that foundation, let me turn to the phase II data for tilrekimig, starting with efficacy. Phase II is a randomized, double-blind, placebo-controlled trial in adults with moderate to severe atopic dermatitis. It includes three stages with tilrekimig. Stage 1 evaluated our highest dose, 450 milligrams every two weeks, in biologic-naive patients. Stage 2 was the dose-ranging portion, and stage 3, from which we've yet to report data, enrolled a biologic-experienced population. Today, we're focusing on stage 2. In stage 2, biologic-naive patients were randomized to placebo or to one of three monthly maintenance doses, 400 milligrams, 200 milligrams, or 50 milligrams, each following a loading dose. The treatment period was 16 weeks. The primary endpoint was EASI-75, measured at week 16. The secondary endpoint measured skin clearance via the validated Investigator's Global Assessment, or vIGA, with responders defined as those achieving at least a 2-point improvement from baseline and a classification of clear or almost clear skin. An exploratory endpoint assessed itch, measured by the Peak Pruritus Numerical Rating Scale, or PP-NRS. Notably, background topical corticosteroids were not permitted, so these results reflect tilrekimig as monotherapy. The trial met its primary endpoint across all tilrekimig doses. At week 16, about 59% of patients at the 400 milligram dose, 61% of patients at the 200 milligrams, and 48% of patients at the 50 milligrams achieved EASI-75, compared with about 9% on placebo. Statistical significance was demonstrated as early as week eight, with response rates continuing to increase over time. Though cross-trial comparisons have inherent limitations, the phase II tilrekimig results on EASI-75 at week 16 suggest the potential for superior efficacy versus dupilumab. At the top monthly doses, from left to right on the slide, tilrekimig treatment led to placebo-adjusted response rates of about 52% at the 200 milligram dose and 49% at the 400 milligram dose. For reference, the placebo-adjusted EASI-75 response rates for dupilumab in its pivotal SOLO 1 and SOLO 2 trials were about 37% and 32%, respectively. On the secondary endpoint of skin clearance, both the 200 and 400 milligram doses of tilrekimig achieved a placebo-adjusted vIGA-AD response rate of about 27% in the phase II trial. This was statistically significant versus placebo and similar to the IGA responses reported for dupilumab in SOLO 1 and SOLO 2. Two points of context. First, the SOLO trials used a sponsor-specific IGA scale, whereas our study used the validated vIGA-AD, a more recently standardized scale. Second, consistent with the EASI-75 trajectory, we anticipate the vIGA response rate will continue to improve with longer dosing. Turning to our exploratory endpoint itch, which is the most prevalent and burdensome symptom of atopic dermatitis and the main reason patients seek care. In an exploratory analysis, we evaluated the proportion of patients achieving a 4-point or greater improvement in the Peak Pruritus Numerical Rating Scale. At week 16, placebo-adjusted response rates were about 44% and 35% in the 200 and 400 milligram groups, respectively. For reference, placebo-adjusted rates in a cross-trial comparison for dupilumab in SOLO 1 and SOLO 2 were about 27%-29%. Notably, tilrekimig's itch benefit emerged early, with statistically significant improvement versus placebo as early as week four. We believe rapid and meaningful itch relief could be an important feature for patients and the physicians who treat them. Here you can see biomarker data from the trial that reinforces our efficacy findings and are consistent with tilrekimig's mechanism of action. Starting with the panel on the left, TARC, or thymus and activation-regulated chemokine, is a well-established biomarker of atopic dermatitis disease activity. At week 16, tilrekimig significantly reduced TARC from baseline in the 200 and 400 milligram dose groups. Turning to the right, the same doses also significantly reduced eosinophils, which are key effector cells in type 2 inflammatory diseases. The observed reduction in eosinophils represents a potential point of differentiation versus dupilumab and may reflect the added mechanism of TSLP blockade with tilrekimig. These results, together with our efficacy and safety data, inform the design and dose selection for our phase III program. tilrekimig was well tolerated with a favorable profile, with no dose-dependent safety signals or serious adverse events related to the study drug. Treatment emergent event rates were comparable between tilrekimig and placebo. Injection site reactions were numerically lower with tilrekimig 400 milligram once monthly than with placebo. No eosinophilia adverse events were reported with either study drug or placebo, and rates of conjunctivitis were similar between study drug and placebo. While cross-trial comparisons have limitations, this profile stands out against historical rates with dupilumab. At doses of up to 400 milligrams once every four weeks, patients on tilrekimig in the phase II trial had lower rates of conjunctivitis and injection site reactions than those reported with dupilumab. This highlights an additional opportunity for potential differentiation as we advance our phase III program. Our phase III program in moderate to severe atopic dermatitis consists of two trials. One randomizes participants 2:2:1 to tilrekimig, dupilumab, or placebo. The co-primary endpoints are EASI-75 and vIGA-AD, with tilrekimig versus placebo at week 16, which represents the traditional regulatory standard for phase III. Key secondary endpoints are testing superiority versus dupilumab. This will allow us to evaluate clear head-to-head evidence against the standard of care biologic. Following a 24-week initial treatment period, a 28-week maintenance period is designed to evaluate continued treatment, extended dosing interval, and generate data on participants switching from dupilumab to tilrekimig. In parallel, a second phase III study of approximately 375 patients is evaluating tilrekimig in combination with background topical therapy, designed to reflect real-world treatment practice. Together, these complementary studies are designed to support a potential BLA submission and demonstrate tilrekimig's potential differentiation in a rigorous, well-controlled setting. Next, I'll speak about our plans for tilrekimig beyond atopic dermatitis. With tilrekimig, we are applying a strategy we plan to use across multiple I&I programs designed to enable multi-indication molecules with development programs run in parallel. First, identify a biological axis that drives multiple diseases with high unmet need, such as the type 2 inflammatory axis. Next, demonstrate clinical proof of concept in an anchor indication, a condition with a large patient population and clear need for new therapies. Finally, strategically expand to additional indications where targeting this axis is expected to drive significant clinical benefit. As mentioned, the first two potential expansion indications for tilrekimig are asthma and COPD. These were chosen for the central roles of TSLP and IL-4/13 signaling in airway inflammation, and for the external clinical data validating both pathways as drug targets. TSLP acts upstream, released by the airway lining in response to triggers like allergens and cigarette smoke. It activates immune cells that initiate type 2 inflammation, while also contributing to other non-type two pathways. IL-4 establishes and amplifies the type 2 inflammatory response, promoting the accumulation of eosinophils and the production of IgE antibodies that drive immune overactivity. IL-13 is an effector. It drives mucus production, promotes tissue remodeling, and makes airways more sensitive and prone to constriction. As I alluded to earlier, approved antibodies validate IL-4/13 and TSLP signaling pathways as targets in respiratory indications. Specifically, IL-4/13 blockade has shown efficacy in type 2 high asthma and in COPD patients with eosinophil counts of 300 per microliter or higher. For anti-TSLP, efficacy in severe asthma was demonstrated across eosinophil levels in a phase III tezepelumab study. Emerging evidence suggests a potential role for TSLP in COPD, particularly in patients with blood eosinophil counts of at least 150 per microliter. Though recent biological approvals in asthma and COPD represent important advances, substantial unmet need persists. Via combined inhibition of IL-4/13 and TSLP with tilrekimig, we believe we can treat patients with asthma and COPD who are not well-served by the current standard of care, subject to clinical trial and regulatory success. These represent meaningful opportunities for patient impact, with approximately 3 million people ages 12 and up diagnosed with severe asthma in the U.S., and about 2.5 million U.S. adults diagnosed with COPD that remains uncontrolled. Here you can see how tilrekimig's trials in asthma and COPD fit into our development strategy. In atopic dermatitis, we aim to demonstrate superiority versus dupilumab in a head-to-head setting. In asthma and COPD, we aim to demonstrate efficacy in a broad range of blood eosinophil counts. Our asthma studies enroll across eosinophil levels. In COPD, we are enrolling patients with blood eosinophil counts greater than or equal to 150 per microliter. This contrasts to dupilumab's pivotal COPD trials, which restricted enrollment to those with counts of at least 300 per microliter. This strategy is designed to clearly differentiate tilrekimig across all three of these potential indications and position it for substantial patient impact. With that, I'll hand it back to Francesca. Thank you, Mike. To summarize, phase II data from our anchor indication support tilrekimig's potential to be a first-in-class trispecific and leading biologic therapy for type 2 inflammatory disorders. We believe tilrekimig has the potential for superior efficacy and safety that compares favorably to the current standard of care biologic, dupilumab, and are evaluating this in phase III. We also have ongoing late-stage studies in asthma and COPD, which together with atopic dermatitis, are projected to represent a global market of more than $55 billion in 2030. Now we will begin the Q&A session with Mike and Christian. As a reminder, our Pfizer Pflash series is designed as an educational deep dive into our pipeline programs. I'll therefore kindly ask that participants keep questions focused on the data, development program, and potential differentiation of tilrekimig that we covered today. Please avoid questions that would require us to provide forward-looking financial projections. While we are happy to clarify any information shared during the presentation, we will not be offering estimates beyond what has already been communicated. With that, we are ready to take the first question. Operator, if you could please assemble the queue. Thank you. If you would like to ask a question, press star one on your keypad. To leave the queue at any time, press star two. Once again, that is star one to ask a question. We will go first today to Chris Schott with JPMorgan. Please go ahead. Hi, this is Ethan on for Chris. Thanks for taking our question. Just wanted to ask, on the trial looking at tilrekimig head-to-head versus DUPIXENT, any color you can provide on the margin for superiority that the study is powered to detect, along with the testing order? Then just more broadly, how you are thinking about the importance of superiority in order to gain kind of broad formulary access. Thank you for taking our questions. Thanks for that question. I am going to give that to Christian Antoni to respond. Thank you, Chris, for the question. We are not currently disclosing the stats plan. We are actually finalizing it. We are strongly powered against DUPIXENT in all the key secondary endpoints at two different time points, so we are very confident that we will have a chance to achieve it if the drug holds on. The second part of the question, obviously, being superior to DUPIXENT will help the product tremendously, but we are not commenting on. Thank you. Operator, we will take the next question. We will go next to Evan Seigerman with BMO Capital Markets. Please go ahead. Hi, this is Cavanaugh for Evan. Thanks for taking our question. Could you maybe speak to the placebo response rate in your phase II study? It seemed a bit lower than what we saw for DUPIXENT in phase III. Do you have any thoughts on what might be driving that? Also, how do you think about this into your phase III studies? Thank you. I'll give this to Christian as well. Thank you, Evan. The placebo rate is lower than we've seen in other trials, but it's a small trial where we paid a lot of attention to the quality of the trial. When you go in the first phase of this trial, you also saw a little bit higher placebo response rate, and when you look at the absolute number of the response rates, it shows that the drug is favoring where it should be, so we feel confident. Going forward into phase III, we learned a lot how to pay attention to the quality of the trials, and we are confident that we will keep the response rates and the delta. Thank you. Thank you. Operator, we'll take the next one. We'll go next to Vamil Divan with Guggenheim Securities. Your line is now open. Great. Thanks for taking the question and for hosting this. Maybe just two for me. One, I don't know if you can comment on this because it is forward-looking, but just as you think about the BLA submission and timelines, maybe just what's your current estimate on when you think this could be brought to the market for atopic dermatitis? The second one, I'm just curious on the asthma COPD side. Obviously, you guys have historically in derm and inflammation, but probably going to be a little bit different. So, I'm just curious how you're thinking about that maybe more as a broader therapeutic area, especially if you're seeing positive signs of moving into this product into asthma and COPD. Thanks. Vamil, it's Francesca. So on the time to market, the only thing that I can tell you right now is just the PCD dates that are published on the various trials. So for the AD trial that's going on right now, the PCD is the first quarter of 2028, and then the third quarter of 2028 for the one versus DUPIXENT, and then on the asthma trials, those are more first half of 2029. So that's probably the best marker I can give you right now for the timelines. I apologize. I had a difficult time hearing the second part of the question. Could you repeat that, please? Yeah, it was just more focused on the pulmonary space more generally, if you're moving into areas like asthma, COPD. I'm just curious, is this turning into more of an area of focus for Pfizer? Obviously, you're in inflammation and internal medicine. I'm just curious more about this pulmonary space specifically, and if you see promise for this product moving into that space, would you, if the scenarios like to build up further? Yeah, I think that's absolutely the case. With a molecule like tilrekimig, to really realize its full potential, we need to expand into the respiratory space, and we look more broadly at that area as an area with a lot of unmet need as well as a good fit with some of our mechanisms. Thank you. Operator, we'll take- Oh, sorry, Vamil. Are you good? No, I'm good. Yeah, I was just saying thanks. Okay. Thank you, Vamil. Operator, we will take the next question. We will go next to Geoff Meacham with Citi. Please go ahead. Hey, guys. This is Nishant on for Geoff. Thanks for taking our questions and the presentation today. Maybe one broader question. Your target profile for tilrekimig emphasizes superior efficacy versus Dupi, but market entry could coincide with less frequent biologics such as zumilokibart or maybe oral agents such as Kymera's STAT6 inhibitor. What does your market research suggest physicians and patients value most among maybe incremental efficacy, safety, dosing, and oral administration? What minimum efficacy advantage would tilrekimig need to overcome these convenience differences? Thank you. Go ahead, Christian. Okay, so I take that one. The question was, let's start with the patient's preference and the convenience piece. Obviously, a subcu biologic is a very convenient drug. There are some patients who will prefer orals, but I think the difference is really also not just in the patient convenience piece, it is also the medical need. The biologics, especially here with the three targets which you combine, is a very strong therapy which will find its place among all these therapies which are coming. We are very confident that the patient need and also patient preference for monthly dosing will be there. Could you remind me the first part of the question? I did not really understand it completely. Second one, right? Nishant? Yeah. Sorry. I mean, right. We apologize. The IVs have been a little bit challenging, so we are just having trouble hearing all of you across the board. If you would not mind, just everybody speaking up a tad, because it is not just you. We just cannot hear as well. Yeah. Just your thoughts on market research, because it looks like tilrekimig could enter market with multiple other drugs, like zumi, which is once every three months and six months. Maybe talk about how the physicians, like your interactions with them, gives you any insight on how this drug could be competitive versus zumi, which could be every three, every six months, or the overall statistics. Thank you. Yeah. As I said earlier, patients' preference will play a role, and some patients will go to more extended dosing, no question. But at the end of the day, the benefit-risk ratio of these drugs will, I think, the primary rule. When you have a drug which is superior in the efficacy and very safe, I think it will find its place and dominate the convenience discussion. Great. Thank you. Thank you. Thank you, Christian. Thanks, Nishant. Operator, we will go to the next question, please. We'll go next to Dave Risinger with Leerink Partners. Your line is now open. Thanks very much, and thanks for hosting this session, and congrats on the phenomenal data. I wanted to step back to a little bit higher level here. I'm very interested in the history of tilrekimig. Obviously this was internally developed by Pfizer. Could you talk about that history and discuss which research site gets the credit for it? Thank you. Yes. Thanks for the question, Dave. This is a molecule that was conceived, discovered, and developed at the Cambridge Kendall Square site, and really goes back to our days at Wyeth, when Wyeth was actually the first company to discover the IL-13 pathway and had a couple of IL-13 agents in the clinic over a decade ago. When we conceived this molecule, part of the appealing strategy was to combine the different mechanisms into a single molecule. As you see with some programs today, individual monoclonals are sometimes given in combination. But from a complexity standpoint, in particular deciding on the best dose, we thought it was much more straightforward to design in a fixed potency across the three molecules and then have a single program where you can just do a single dose-ranging study to establish the most efficacious dose. It's a molecule with quite a bit of history and came from the Cambridge site. How long is the exclusivity? Want to take it back to him? Yeah. Dave, we'll get back to you. We'll look it up and get back to you. Wonderful. All right. Okay. Thank you again. Okay. Thanks, Dave. Operator, we will take the next question. We will go next to Louise Chen with Scotiabank. Your line is now open. Hi, this is Hannah on for Louise. I had a question about the use of topical corticosteroids. Because the phase II evaluated tilrekimig as a monotherapy without the background use of steroids, how should we think about the potential incremental response when combined with these topical therapies in the phase III? Do you believe that adding topical therapy would make it harder to demonstrate the drug's intrinsic differentiators? I'll give that to Christian as well. It's a very common trial design in atopic dermatitis that you have trials in combination with topical steroids and trials without combination of the steroids. We have no doubt that tilrekimig will fare as the other drugs and will show a very nice response against placebo and in combination. Thank you, Christian. Operator, we'll go to the next one. We'll go next to Steve Scala with TD Cowen. Your line is now open. Oh, thank you very much. I have three brief questions. First, are the dupilumab doses being used in phase III identical to phase II? Second, given the three mechanisms of tilrekimig, are drug interactions hard to prove or disprove, and how are you attacking that? Lastly, do you know if agents that combine these same three mechanisms are being developed by competitors, particularly perhaps in China? Thank you. I'll take the first question. On the, yeah, the dose. Yeah, dupilumab was not included in our phase II study, so we'll be using these labeled doses of dupilumab in the phase III study. Then the DDI was the second question. I mean, DDIs, generally speaking, are not a significant issue in the context of biologics. So we are not anticipating DDI issues as a component of the program going forward. Competitors and if anything is emerging in China. Yeah, I personally do not know of any identical or very similar molecules coming out of China at the moment, but I would not at all be surprised if there are. Thank you. Thank you, Steve. Okay, operator, we'll go to the next one. We'll go next to Jason Gerberry with Bank of America. Your line is now open. Hey. Thank you guys for taking my questions. One, just as you guys contemplate the trial design, realize you're not speaking to the statistics plan, but just curious if you can speak to the trend in the field. I think what we've observed on at least EASI-75, kind of phase II to phase III effect size compression, kind of in that 8% range. So just wondering if we're in the right ballpark thinking about how single agent activity could evolve going from phase II to phase III. And then my second question is, in the phase II asthma trial, wondering, I don't know if you think this is the right comp, but Sanofi's IL-13 TSLP didn't look like it was much better than TEZSPIRE on cross-trial comparison. So kind of curious what underpins your confidence with your trispecific approach showing benefit over TEZSPIRE. Thanks. I'll take the second question first. Thanks, Jason. In our hands, the Sanofi molecule is not a particularly robust inhibitor of IL-13, so we think it's difficult to draw any firm conclusions about the mechanisms from that particular agent. And the first question? First question, I'll take. I can take this, the general question, if we would have an erosion in the response rate from phase II to phase III. Atopic dermatitis, not as good as psoriasis, but in general, doesn't erode that bad like other diseases like rheumatoid arthritis, et cetera, when you look across the spectrum. So we hope that your 8%, we think it's a little bit smaller than that one. And what I mentioned earlier about the placebo response, the quality control, we learned a lot in this phase II trial. Atopic dermatitis is now a field where you really have to look at each site individually. We look at each patient individually with the pictures before we include them. So we are confident that going forward, we can control these erosions. Very good. Thank you. Thanks, Jason. Operator, we'll go to the next one. We'll go next to Michael Yee with UBS. Please go ahead. Great. Good morning. This is Matt on for Mikey from UBS. Thank you so much for the presentation. I wanted to ask if you could just expand a bit on how you feel the incremental contribution of TSLP is here, and what gives you confidence that the TSLP component is really adding something versus just kind of hitting IL-4 and IL-13 more strongly. Just thinking about that in the context of the historical TSLP trials in atopic derm. Thanks so much. Thanks for the question, Michael. As I showed in the slides through the presentation, with our skin explant data, we see, as you would expect, based on where the receptors are expressed across different subsets of cells, that in fact, we do see highly complementary pathways activated by the two different sets of cytokines. In the case of IL-13, it's expressed very broadly, whereas TSLP is much more limited in its expression to immune cells. As you point out, the monotherapy efficacy in atopic dermatitis with TSLP has been underwhelming, but I think there's a clear signal with TSLP and understanding that all of the pathways that are blocked by four and 13 still leave behind a significant number of type 2 pathways that are still active, we think is a very strong biological rationale and consistent with the greater benefit that we've seen, at least compared to historical results. Thank you. Thanks, Matt. Operator, we'll go to the next one. We'll go next to Courtney Breen with Bernstein. Please go ahead. Hi, guys. Thanks for taking my question. This is Woody Pogglayes on for Courtney. Just a question on drug presentation. We noted on ct.gov you're running a phase I, combining the drug with hyaluronidase. Just wondering why this is necessary if the drug's already subcutaneous. Is this due to volume of administration, patient pain, or is this broader PK/PD or something else? Thank you very much. Yeah. Thanks for the question, Courtney. We're always looking for the most patient-friendly formulation, and the study that's on clinicaltrials.gov is just an additional assessment that we're doing to try to understand how we can bring the most favorable, patient-friendly formulation to patients when we launch. Thank you. Thanks for the question. Operator, it looks like we have one last question, so we will take that. Our final question comes from Akash Tewari with Jefferies. Please go ahead. Hey, this is Manoj on for Akash. Just one question. How do you think about the dose response you observed in phase II, and how important is that dose selection going into phase III, especially when you are considering a subcutaneous formulation going forward? Just wondering about that. Thanks for the question, Akash. There's really not much more important than dose selection coming out of phase II, so we spend a lot of time thinking about that. I think in some of the slides presented today, you could see a clear dose response, particularly with the biomarkers, which is often the most faithful representation of dose response. And we see a clear plateau and feel very confident about the dose we're taking forward. Yep. Thank you. Okay. Operator, it looks like there's one last one. If we can It just popped up. Certainly. We'll go next to Nick Esposito with RBC Capital Markets. Hi, team. Thank you for taking our question. We were just curious on when the phase II data could read out. We noticed the PCD date is actually today on ct.gov, and if that will inform anything for the phase III studies. Thank you. Thanks for the question, Nick. Typical time to lock databases and turn around might be on the order of a couple months. We've already looked at interim data internally from that study, and it's met our expectations in terms of the response rate in patients who've been previously exposed to biologics. We don't really anticipate any program-changing data coming from that study. Christian, would you like to add something? Yeah. To be specific, it will be presented at one of the next scientific congresses. Thank you. Thank you, Nick. Okay, with that being our last question, I first want to, before we close it down, I want to come back to Risinger's question on exclusivity, and just for everybody's benefit. The patent applications are pending approval, but right now, the U.S. and EU5 date would be February of 2043 for exclusivity. Dave, thank you for that question. Hopefully that answers it. With that, I would like to thank Mike and Christian for their time today, and I'd also like to thank everyone for joining the webcast, and to our analysts for their questions. I know there's a lot of interest in this program. If there's any remaining questions, the IR team is always available to receive your questions, so please reach out. With that, thanks for joining, and we wish everyone a great day. Thank you. This brings us to the end of today's program. We appreciate your time and participation. You may now disconnect.